![[Asn23]-beta-Amyloid (1-42), iowa mutation](https://file.medchemexpress.com/product_pic/hy-p5331.gif "Click to View [Asn23]-beta-Amyloid (1-42), iowa mutation Product Detail")
Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
41 Results for "
β-amyloid protein (APP)
" in MedChemExpress (MCE) Product Catalog:
Products (41)
41 Results for "β-amyloid protein (APP)" in MCE Product Catalog:
2
2 Cited Publications
Target:
Research Areas:
AZD3839 is an orally available, selective, reversible inhibitor of the β-site amyloid precursor protein cleaving enzyme BACE1 that can cross the blood-brain barrier. AZD3839 inhibits recombinant human BACE1 with a Ki=26.1 nM. AZD3839 inhibits A40 production in SH-SY5Y cells with an IC50 of 4.8 nM. AZD3839 binds to BACE1 and reduces the Aβ amyloid produced by the cleavage of amyloid precursor protein (APP) by BACE1 and γ-secretase. AZD3839 can be used in the field of Alzheimer's disease research .
1
Target:
Research Areas:
Buntanetap ((+)-Phenserine) is a selective acetylcholinesterase inhibitor. Buntanetap is a multiple neurotoxic protein translation inhibitor with oral activity, including amyloid precursor protein (APP), α-synuclein (αSYN) and huntingtin protein (HTT). Buntanetap reduces the production of β-amyloid precursor protein by blocking its mRNA translation. Buntanetap has anti-inflammatory effects and can be used in the study of Alzheimer's disease and Parkinson's disease .
1
1 Cited Publications
Cat. No.: HY-16009B
CAS No.: 865795-23-9
Synonyms: (+)-Phenserine L-Tartrate; ANVS401 L-Tartrate
Target:
Research Areas:
Buntanetap L-Tartrate (Phenserine L-Tartrate) is a selective AChE inhibitor (IC50 = 22.2 nM). Buntanetap is a multiple neurotoxic protein translation inhibitor with oral activity, including amyloid precursor protein (APP), α-synuclein (αSYN) and huntingtin protein (HTT). Buntanetap reduces the production of β-amyloid precursor protein by blocking its mRNA translation. Buntanetap has anti-inflammatory effects and can be used in the study of Alzheimer's disease and Parkinson's disease .
1
1 Cited Publications
Cat. No.: HY-P704352
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: APP; PreA4; Prev. AD1; CVAP; Alzheimer Disease amyloid A4 protein Homolog; Beta-amyloid Precursor protein; amyloid-Beta Precursor protein; Testicular Tissue protein Li 2; amyloid Precursor protein; Beta-amyloid Peptide(1-40); Alpha-SAPP; Beta-amyloid Pept
Species:
Human
Source:
HEK293
Synonyms: (-)-Eseroline phenylcarbamate; (-)-Phenserine
Target:
Research Areas:
Phenserine ((-)-Eseroline phenylcarbamate) is a derivative of Physostigmine (HY-N6608) and is a potent, noncompetitive, long-acting and selective AChE inhibitor. Phenserine reduces β-amyloid precursor protein (APP) and β-amyloid peptide (Aβ) formation. Phenserine improves cognitive performance and attenuates the progression of Alzheimer's disease .
Cat. No.: HY-171347
CAS No.: 1255700-88-9
Target:
Research Areas:
gamma-secretase modulator 6 (Example 50) is a gamma-secretase modulator. gamma-secretase modulator 6 inhibits Aβ42 secretion in HEK cell line stably expressing APP (Aβ amyloid precursor protein) (pIC50: 8.1). gamma-secretase modulator 6 can be used for research of Alzheimer's disease .
Cat. No.: HY-177646
CAS No.: 2572991-83-2
Synonyms: ALN-APP
Research Areas:
Mivelsiran (ALN-APP) is an siRNA targeting the β-amyloid precursor protein (APP). Mivelsiran induces sequence-specific degradation of APP mRNA via RNA interference, thereby reducing the levels of APP protein and downstream amyloid cleavage products. Mivelsiran reduces β-amyloid protein levels in the brain, alleviates neuroinflammation, and attenuates microglial proliferation. Mivelsiran can be used for research on early-onset Alzheimer's disease .
Cat. No.: HY-P1894
CAS No.: 315229-44-8
Target:
Research Areas:
Cat. No.: HY-177646A
Synonyms: ALN-APP sodium
Research Areas:
Mivelsiran (ALN-APP) sodium is an siRNA targeting the β-amyloid precursor protein (APP). Mivelsiran sodium induces sequence-specific degradation of APP mRNA via RNA interference, thereby reducing the levels of APP protein and downstream amyloid cleavage products. Mivelsiran sodium reduces β-amyloid protein levels in the brain, alleviates neuroinflammation, and attenuates microglial proliferation. Mivelsiran sodium can be used for research on early-onset Alzheimer's disease .
Cat. No.: HY-P1894A
Target:
Research Areas:
Cat. No.: HY-P10180
CAS No.: 148914-01-6
Synonyms: APP (319-335)
Target:
Research Areas:
Cat. No.: HY-13438A
CAS No.: 1421852-78-9
Target:
Research Areas:
AZD3839 fumarate is an orally available, selective, reversible inhibitor of the β-site amyloid precursor protein cleaving enzyme BACE1 that can cross the blood-brain barrier. AZD3839 fumarate inhibits recombinant human BACE1 with a Ki=26.1 nM. AZD3839 fumarate inhibits A40 production in SH-SY5Y cells with an IC50 of 4.8 nM. AZD3839 fumarate binds to BACE1 and reduces the Aβ amyloid produced by the cleavage of amyloid precursor protein (APP) by BACE1 and γ-secretase. AZD3839 fumarate can be used in the field of Alzheimer's disease research .
Cat. No.: HY-P2551
Target:
Research Areas:
Cat. No.: HY-103374A
CAS No.: 156910-61-1
Synonyms: (-)-Eseroline phenylcarbamate tartrate; (-)-Phenserine (+)-tartrate
Target:
Research Areas:
Phenserine tartrate ((-)-Eseroline phenylcarbamate) is a derivative of Physostigmine (HY-N6608) and is a potent, noncompetitive, long-acting and selective AChE inhibitor. Phenserine tartrate reduces β-amyloid precursor protein (APP) and β-amyloid peptide (Aβ) formation. Phenserine tartrate improves cognitive performance and attenuates the progression of Alzheimer's disease .
Cat. No.: HY-P10163
Target:
Research Areas:
Cat. No.: HY-129133
CAS No.: 168037-22-7
Category:
Target:
Cat. No.: HY-P5331
Target:
Research Areas:
Cat. No.: HY-177646C
Target:
Research Areas:
FAM labled Mivelsiran (ALN-APP) sodiumis a FAM labled Mivelsiran sodium. Mivelsiran sodium is an siRNA targeting the β-amyloid precursor protein (APP). Mivelsiran sodium induces sequence-specific degradation of APP mRNA via RNA interference, thereby reducing the levels of APP protein and downstream amyloid cleavage products. Mivelsiran sodium reduces β-amyloid protein levels in the brain, alleviates neuroinflammation, and attenuates microglial proliferation. Mivelsiran sodium can be used for research on early-onset Alzheimer's disease .
Cat. No.: HY-177646D
Target:
Research Areas:
Cy3 labled Mivelsiran (ALN-APP) sodium is a Cy3 labled Mivelsiran sodium. Mivelsiran sodium is an siRNA targeting the β-amyloid precursor protein (APP). Mivelsiran sodium induces sequence-specific degradation of APP mRNA via RNA interference, thereby reducing the levels of APP protein and downstream amyloid cleavage products. Mivelsiran sodium reduces β-amyloid protein levels in the brain, alleviates neuroinflammation, and attenuates microglial proliferation. Mivelsiran sodium can be used for research on early-onset Alzheimer's disease .
Cat. No.: HY-P992157
Synonyms: murine version of Bapineuzumab
Target:
Research Areas:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
